## **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup>: C12N 5/06, A61K 38/22, 38/26, C07K 14/605, 14/575, A61P 5/50

A3

(11) International Publication Number:

WO 00/09666

' [ ,

(43) International Publication Date:

24 February 2000 (24.02.00)

(21) International Application Number:

PCT/US99/18099

(22) International Filing Date:

10 August 1999 (10.08.99)

(30) Priority Data:

60/095,917

10 August 1998 (10.08.98) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US

60/095,917 (CON)

Filed on

10 August 1998 (10.08.98)

(71) Applicant (for all designated States except US): THE GOV-ERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors'Applicants (for US only): EGAN, Josephine [US/US]; 2421 Everton Road, Baltimore, MD 21209 (US). PERFETTI, Riccardo [US/IT]; 1729 Corcoran Street, N.W., Washington, DC 20009 (US). PASSANITI, Antonino

[US/US]; 18315 Peters Avenue, White Hall, MD 21161 (US). GREIG, Nigel [US/GB]; 14415 Long Green Drive, Silver Springs, MD 20906 (US). HOLLOWAY, Harold [US/US]; 121 Mariners Point Drive, Middle River, MD 21220 (US).

(74) Agents: SPRATT, Gwendolyn, D. et al.; Needle & Rosenberg, P.C., The Candler Building, Suite 1200, 127 Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report: 23 November 2000 (23.11.00)

(54) Title: DIFFERENTIATION OF NON-INSULIN PRODUCING CELLS INTO INSULIN PRODUCING CELLS BY GLP-1 OR

(S4) Title: DIFFERENTIATION OF NON-INSULIN PRODUCING CELLS INTO INSULIN PRODUCING CELLS BY GLP-1 OF EXENDIN-4 AND USES THEREOF

#### (57) Abstract

The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
Cl	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	Li	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		
ĺ							

PCT/US 99/18099

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N5/06 A61K A61K38/22 A61K38/26 C07K14/605 C07K14/575 A61P5/50 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X MASHIMA ET AL: "FORMATION OF 31 INSULIN-PRODUCING CELLS FROM PANCREATIC ACINAR AR42J CELLS BY HEPATOCYTE GROWTH FACTOR" ENDOCRINOLOGY, vol. 137, no. 9, 1996, pages 3969-3976, XP000670297 ISSN: 0013-7227 cited in the application Α 1,2,4-6,9,12,13, 15-17, 20,23, 25,27, 29,32,33 abstract; figure 8 page 3974, left-hand column page 3975, right-hand column Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or involve an inventive step when the document is taken alone which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 2 1. JUNE 2000 15 June 2000 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Ceder, 0

Inter. anal Application No
PCT/US 99/18099

		FC1/03 99/18099
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 31214 A (LONDON HEALTH ASS ;DUPRE JOHN (CA)) 23 November 1995 (1995-11-23) page 1, line 31 - line 34 page 2, line 32 -page 3, line 20 page 4, line 26 - line 30	34
X	US 5 424 286 A (ENG J) 13 June 1995 (1995-06-13) abstract	36
<b>A</b>	GEFEL ET AL: "GLUCAGON-LIKE PEPTIDE-I ANALOGS: EFFECTS ON INSULIN SECRETION AND ADENOSINE 3',5'-MONOPHOSPHATE FORMATION" ENDOCRINOLOGY, vol. 126, no. 4, 1990, pages 2164-2168, XP000574862 ISSN: 0013-7227	
Α	THORENS B ET AL: "CLONING AND FUNCTIONAL EXPRESSION OF THE HUMAN ISLET GLP-1 RECEPTORÖDEMONSTRATION THAT EXENDIN-4 IS AN AGONIST AND EXENDIN-(9-39) AN ANTAGONIST OF THE RECEPTOR" DIABETES, vol. 42, no. 11, 1 November 1993 (1993-11-01), pages 1678-1682, XP000571435 ISSN: 0012-1797 cited in the application	
E	WO 99 43705 A (NOVONORDISK AS) 2 September 1999 (1999-09-02) abstract	34

Ir...national application No. PCT/US 99/18099

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: — because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy Although claims 34-52 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.
page 1 of 2

In .national application No. PCT/US 99/18099

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: effects of the compound/composition.
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.
nage 2 of 2

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11, 23-26, 31, 32, 34, 35, 39-52

A method of differentiating non-insulin producing cells into insulin producing cells by contacting the cells with a growth factor, cells produced by the method and uses of the method or the cells for treating subjects diagnosed with type 1 diabetes, where the growth factor is GLP-1, peptides substantially homologous to GLP-1 or fragments thereof.

2. Claims: 12-22, 27-30, 33, 36-38

A method of differentiating non-insulin producing cells into insulin producing cells by contacting the cells with a growth factor, cells produced by the method and use of the method for treating subjects diagnosed with type 1 diabetes, where the growth factor is Exendin-4, peptides substantially homologous to Exendin-4 or fragments thereof.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 34-52 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT — Method for treatment of the human or animal body by therapy

information on patent family members

Inter anal Application No
PCT/US 99/18099

Patent document cited in search report	:	Publication date	Patent family member(s)	Publication date
WO 9531214	Α	23-11-1995	AU 711611 B AU 2404495 A CA 2190112 A EP 0762890 A JP 10500114 T	14-10-1999 05-12-1995 12-05-1995 19-03-1997 06-01-1998
US 5424286	Α	13-06-1995	NONE	
WO 9943705	Α	02-09-1999	AU 2610599 A	15-09-1999

THIS PAGE BLANK (USPTO)